ALKS

Alkermes Plc

ALKS, USA

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

https://www.alkermes.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALKS
stock
ALKS

Campbell & CO Investment Adviser LLC Has $741,000 Position in Alkermes plc $ALKS MarketBeat

Read more →
ALKS
stock
ALKS

Precision Trading with Alkermes Plc (ALKS) Risk Zones Stock Traders Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$43.6875

Analyst Picks

Strong Buy

8

Buy

1

Hold

6

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

15.74

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

3.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.77 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

3.55 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

21.40 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.34

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 104.39% of the total shares of Alkermes Plc

1.

BlackRock Inc

(16.8745%)

since

2025/06/30

2.

Vanguard Group Inc

(11.2087%)

since

2025/06/30

3.

T. Rowe Price Associates, Inc.

(6.0831%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.9402%)

since

2025/08/31

5.

State Street Corp

(4.9724%)

since

2025/06/30

6.

Baker Bros Advisors LP

(3.8834%)

since

2025/06/30

7.

Renaissance Technologies Corp

(3.5196%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.1498%)

since

2025/07/31

9.

JPMorgan Chase & Co

(2.9297%)

since

2025/06/30

10.

RTW INVESTMENTS, LLC

(2.8364%)

since

2025/06/30

11.

T. Rowe Price Mid-Cap Value

(2.5916%)

since

2025/07/31

12.

Geode Capital Management, LLC

(2.4374%)

since

2025/06/30

13.

Vanguard Small Cap Index

(2.4235%)

since

2025/07/31

14.

iShares Russell 2000 ETF

(2.3729%)

since

2025/08/31

15.

T. Rowe Price US Mid-Cap Value Equity

(2.3176%)

since

2025/06/30

16.

American Century Companies Inc

(2.2155%)

since

2025/06/30

17.

Dimensional Fund Advisors, Inc.

(1.8759%)

since

2025/06/30

18.

PRIMECAP Management Company

(1.7583%)

since

2025/06/30

19.

venBio Select Advisor LLC

(1.7567%)

since

2025/06/30

20.

Holocene Advisors, LP

(1.7287%)

since

2025/06/30

21.

Avantis US Small Cap Value ETF

(1.6215%)

since

2025/08/30

22.

COMMODORE CAPITAL LP

(1.4841%)

since

2025/06/30

23.

Vanguard Small Cap Growth Index Inv

(1.368%)

since

2025/07/31

24.

Bank of America Corp

(1.3055%)

since

2025/06/30

25.

T. Rowe Price U.S. Mid-Cap Val Eq Tr-D

(1.2803%)

since

2025/06/30

26.

Loomis, Sayles & Company LP

(1.2781%)

since

2025/06/30

27.

Charles Schwab Investment Management Inc

(1.2673%)

since

2025/06/30

28.

Nuveen, LLC

(1.2407%)

since

2025/06/30

29.

SPDR® S&P Biotech ETF

(1.1926%)

since

2025/08/31

30.

NORGES BANK

(1.1291%)

since

2025/06/30

31.

Vanguard Capital Opportunity Inv

(1.0879%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0736%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.9854%)

since

2025/06/30

35.

JPM US Mid Cap Growth-Composite

(0.7982%)

since

2025/06/30

36.

JPMorgan Mid Cap Growth I

(0.7956%)

since

2025/07/31

37.

Vanguard Explorer Inv

(0.7132%)

since

2025/06/30

38.

First Trust NYSE Arca Biotech ETF

(0.6813%)

since

2025/08/28

39.

T. Rowe Price Health Sciences

(0.6715%)

since

2025/07/31

40.

Vanguard Tax-Managed Small Cap Adm

(0.6517%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.417

Latest Release

Date

2025-09-30

EPS Actual

0.6508

EPS Estimate

0.38

EPS Difference

0.2708

Surprise Percent

71.2632%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(7)
Net Net
Possible Net-Net(4)
Quality
High Quality(8)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.